PPD Inc (PPD) Peer Comparison
$0.00
$--
(--%)
As on 07-Jan-2022EDT
Market cap
$16,614 Mln
Revenue (TTM)
$5,879 Mln
P/E Ratio
47
P/B Ratio
0
Div. Yield
0 %
Edit
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
16,614 | 15,933 | 13,215 | 11,972 | 10,883 |
Revenue ($ Mln) |
5,879 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
364.06 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
6.19 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-- | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
47.04 | -- | 271.67 | -- | -- |
Price-To-Book |
-- | 123.68 | 18.72 | 1.79 | 130.86 |
Income Statement ($ Mln)
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,681.47 | 8.25 | 353.87 | 3,273.30 | 0.00 |
|
Cost of Revenue
|
2,882.80 | 3.09 | 5.58 | 2,026.50 | 0.08 |
|
Gross Profit
|
1,798.67 | 8.25 | 348.29 | 1,246.80 | -0.08 |
|
Operating Expenses
|
1,289.24 | 482.73 | 220.09 | 1,323.60 | 99.14 |
|
Operating Profit (EBIT)
|
509.43 | -474.48 | 128.20 | -76.80 | -99.14 |
|
Other Income
|
-- | 5.65 | 3.40 | 178.30 | -3.81 |
|
Profit before Tax
|
187.55 | -505.49 | 131.60 | -672.00 | -102.90 |
|
Provision for Tax
|
18.81 | -21.56 | 25.59 | -111.90 | 2.49 |
|
Profit after Tax (Net Income)
|
153.69 | -448.72 | 106.01 | -560.10 | -102.90 |
|
Minority Interest
|
-- | 48.35 | -- | -- | -- |
|
Consolidated Profit
|
120.15 | -448.72 | 106.01 | -560.10 | -102.90 |
Liabilities ($ Mln)
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-746.52 | 57.91 | 523.34 | 8,476.00 | 113.79 |
|
Minority Interest
|
-- | 48.35 | -- | -- | -- |
|
Non-Current Liabilities
|
4,762.80 | 500.05 | 37.84 | 7,140.00 | 48.90 |
|
Current Liabilities
|
2,277.56 | 95.65 | 10.55 | 2,077.00 | 23.44 |
|
Total Liabilities
|
6,293.84 | 703.59 | 571.73 | 17,693.00 | 186.13 |
Assets ($ Mln)
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,747.64 | 60.76 | 47.48 | 14,276.00 | 2.11 |
|
Current Assets
|
2,546.20 | 642.82 | 524.25 | 3,417.00 | 184.02 |
|
Total Assets
|
6,293.84 | 703.59 | 571.73 | 17,693.00 | 186.13 |
|
Total Debt*
|
4,451.73 | 495.79 | 2.55 | 6,127.00 | 50.12 |
|
Net Current Assets
|
268.64 | 547.18 | 431.01 | 1,340.20 | 160.59 |
Cashflow ($ Mln)
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
251.33 | -399.71 | 151.97 | -41.00 | -78.46 |
|
Cash Flow from Investing Activities
|
-145.89 | -52.99 | -119.26 | -4,779.20 | -0.05 |
|
Cash from Financing Activities
|
280.72 | 447.19 | 12.21 | 4,953.90 | 42.41 |
|
Net Cash Inflow / Outflow
|
-- | -5.52 | 44.92 | 133.70 | -36.09 |
Ratios
Profitability Ratios
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
4.49 | -85.15 | 23.54 | -4.98 | -56.76 |
|
ROE (%)
|
-8.92 | -192.44 | 23.70 | -7.99 | -70.36 |
|
ROA (%)
|
2.59 | -67.21 | 21.55 | -4.20 | -50.60 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
3.28 | -3,228.69 | 29.67 | -16.23 | 2,698.78 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.16 | -0.80 | 0.15 | 0.07 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
221.39 | -72.30 | 12.56 | -924.89 | -50.56 |
|
EPS Growth (%)
|
1.60 | -0.70 | 0.08 | -7.36 | -0.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
77.26 | -18.86 | 31.44 | -26.62 | -29.57 |
|
Price / Book Value
|
-15.91 | 146.12 | 6.37 | 1.76 | 26.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
23.21 | -17.87 | 19.12 | 22,826.39 | -29.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-5.96 | 8.56 | 0.00 | 0.72 | 0.44 |
|
Short term debt to equity ratio
|
-0.12 | 0.09 | 0.00 | 0.07 | 0.01 |
|
Current Ratio
|
1.12 | 6.72 | 49.67 | 1.65 | 7.85 |
|
Quick Ratio
|
-- | -- | 47.67 | 0.89 | -- |
|
Interest Coverage
|
-- | -12.79 | 22.74 | -3.31 | -39.12 |
Operating Efficiency Ratios
| PPD Inc (PPD) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
34.86 | 7.01 | 7.40 | 32.90 | -- |
|
Asset Turnover
|
0.79 | 0.01 | 0.72 | 0.25 | 0.00 |
|
Receivable days
|
116.49 | 125.97 | 23.80 | 109.74 | -- |
|
Inventory Days
|
-- | -- | 869.64 | 236.89 | -- |
|
Payable days
|
19.41 | 1,052.52 | 591.88 | 65.21 | 57,447.40 |
|
Cash Conversion Cycle
|
-- | -- | 301.57 | 281.42 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
